The Combination of Homocysteine and C-Reactive Protein Predicts the Outcomes of Chinese Patients with Parkinson’s Disease and Vascular Parkinsonism

Limin Zhang*, Junqiang Yan*, Yunqi Xu, Ling Long, Cansheng Zhu, Xiaohong Chen, Ying Jiang, Lijuan Yang, Lianfang Bian, Qing Wang*

Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, People’s Republic of China

Abstract

**Background:** The elevation of plasma homocysteine (Hcy) and C-reactive protein (CRP) has been correlated to an increased risk of Parkinson’s disease (PD) or vascular diseases. The association and clinical relevance of a combined assessment of Hcy and CRP levels in patients with PD and vascular parkinsonism (VP) are unknown.

**Methodology/Principal Findings:** We performed a cross-sectional study of 88 Chinese patients with PD and VP using a clinical interview and the measurement of plasma Hcy and CRP to determine if Hcy and CRP levels in patients may predict the outcomes of the motor status, non-motor symptoms (NMS), disease severity, and cognitive declines. Each patient’s NMS, cognitive deficit, disease severity, and motor status were assessed by the Nonmotor Symptoms Scale (NMSS), Mini-Mental State Examination (MMSE), the modified Hoehn and Yahr staging scale (H&Y), and the unified Parkinson’s disease rating scale part III (UPDRS III), respectively. We found that 100% of patients with PD and VP presented with NMS. The UPDRS III significantly correlated with CRP (P = 0.011) and NMSS (P = 0.042) in PD patients. The H&Y was also correlated with Hcy (P = 0.002), CRP (P = 0.000), and NMSS (P = 0.023) in PD patients. In VP patients, the UPDRS III and H&Y were not significantly associated with NMSS, Hcy, CRP, or MMSE. Strong correlations were observed between Hcy and NMSS as well as between CRP and NMSS in PD and VP.

**Conclusions/Significance:** Our findings support the hypothesis that Hcy and CRP play important roles in the pathogenesis of PD. The combination of Hcy and CRP may be used to assess the progression of PD and VP. Whether or not anti-inflammatory medication could be used in the management of PD and VP will produce an interesting topic for further research.

Citation: Zhang L, Yan J, Xu Y, Long L, Zhu C, et al. (2011) The Combination of Homocysteine and C-Reactive Protein Predicts the Outcomes of Chinese Patients with Parkinson’s Disease and Vascular Parkinsonism. PLoS ONE 6(4): e19333. doi:10.1371/journal.pone.0019333

Editor: Joe Z. Tsien, Georgia Health Sciences University, United States of America

Received January 23, 2011; Accepted March 27, 2011; Published April 27, 2011

Copyright: © 2011 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by a Grant-In-Aid from the Third Affiliated Hospital of Sun Yat-Sen University and the Fundamental Research Funds for the Central Universities (Grant No. A77 and 10ykzd08), and the Program for New Century Excellent Talents in University (NCET2010, P.R.China) to Q.W. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: denniswq@yahoo.com

† These authors contributed equally to this work.

Introduction

Idiopathic Parkinson’s disease (PD) is the second most common neurodegenerative disorder following Alzheimer’s disease; however, attention has recently been drawn to vascular parkinsonism (VP). Inflammatory mechanisms have been recognized to play important roles in the pathogenesis and development of PD and VP, and various inflammatory biomarkers have been investigated as potential predictors of PD and VP. Several lines of research have shown that serum oxidative stress and pro-inflammatory cytokines such as interleukin (IL)-1β, IL-2, IL-6, HLA-DRB1, phospholipase A2, tumor necrosis factor (TNF)-α, and TNF-α receptors are elevated in the brain and cerebral spinal fluid of PD patients [1,2,3,4].

In addition to these inflammatory related mediators, plasma C-reactive protein (CRP), and homocysteine (Hcy) levels have recently attracted wide clinical attention as predictive of PD progression. One clinical study by Song indicated that CRP levels in an early PD group were higher than those of healthy controls [5]. A similar result has been observed in another study, which demonstrated an elevated serum CRP in PD and ischemic cerebrovascular disease compared to control subjects [6]. It has been documented that the plasma concentration of Hcy is elevated in PD patients, and this increase is associated with the long-term effects of chronic or acute administration of L-dopa [7,8,9,10]. Investigations on the association of Hcy with PD dementia (PDD) have shown conflicting results [11]; some studies did not observe a direct relationship between Hcy plasma levels and cognitive impairment and dementia in PD [7,12], while others found a significant correlation of hyperhomocysteinemia with the presence of dementia in PD [8,13]. However, to the best of our knowledge, few studies have been performed to investigate the combined effects of Hcy and CRP in PD and VP.

PD patients are characterized by typical motor symptoms (MS), such as bradykinesia, resting tremor, and rigidity, as well as non-
motor symptoms (NMS) [14], which are also highly prevalent. Patients normally show an increasing severity of NMS as the disease develops, although some of the NMS, such as depression and impaired cognition, may occur in the premotor stage of this disease [15]. Whether the severity and progression of PD and VP, as measured by MS and NMS, could be evaluated by the combination of Hcy and CRP is an interesting topic. We undertook this study to determine whether plasma Hcy and CRP levels in patients with PD and VP are associated with the development of the diseases and their cognitive dysfunctions. The primary aim of this study was to use different clinical parameters to compare PD and VP and to describe the correlation between the symptom scores and plasma Hcy and CRP levels in patients with PD and VP. An additional aim was to assess whether Hcy and CRP in PD and VP are associated with poor motor function and L-dopa dosage. A third aim of this study was to conduct an exploratory analysis to identify the association of NMSS domains and plasma Hcy/CRP levels.

Methods

Patients

This cross-sectional study was carried out at the Department of Neurology of the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, P. R. China. From July 2009 to December 2010, 43 patients (25 males and 18 females) with PD and a mean age (± SD) of 58.9±13.7 (Table 1) were recruited from the inpatient/outpatient clinic. The patients were identified according to the United Kingdom PD Society Brain Bank (UK-PDSBB) criteria for the diagnosis of idiopathic PD [16]. In addition, 45 patients (23 males and 22 females) with VP and a mean age (± SD) of 67.0±11.6 (Table 1) were recruited according to the Zijlmans’ criteria for the diagnosis of VP [17].

Ethics Statement

The local Ethics Committee of Third Affiliated Hospital of Sun Yat-sen University approved the study, which has been conducted according to the principles expressed in the Declaration of Helsinki. The patients gave informed consent for the investigation. This consent was verbal for those measurements on MMSE, H&Y, UPDRS(III), and NMSS in this study. All those measurements were anonymously in this study. Since those measurements benefit to the therapies of PD and VP patients involved in this study, the ethics committee specifically approved that procedure and wish those measurements become a routine way for the treatment of PD and VP patients in the future. The consent for the measurement of plasma homocysteine and C-reactive protein was written.

Study Design

Experienced neurologists performed the evaluations and completed neurological examinations of the inpatients and outpatients. All patients with PD in this study fulfilled the criteria of the UK-PDSBB [16]. The exclusion criteria were as follows: (1) PD patients with disability due to neurological disorders other than PD, such as cerebrovascular disease, sequelae, or psychosis [18]; (2) PD patients with somatic diseases that could have a potential effect on NMS (e.g., pain syndromes, advanced diabetes mellitus, malignancy, renal, hepatic or heart failure, severe anemia, or any other acute or chronic debilitating or life-threatening disease/state) [19]; (3) PD patients with moderate/severe cognitive impairment, as determined by a Mini-Mental

Table 1. Demographic, motor, and non-motor parameters.

| Clinical parameters | PD             | Min | Max | VP             | Min | Max |
|---------------------|----------------|-----|-----|----------------|-----|-----|
| Gender (n)          |                |     |     |                |     |     |
| Male n(%)           | 25(58.1)       |     |     | 23(51.1)       |     |     |
| Female n(%)         | 18(41.9)       |     |     | 22(49.9)       |     |     |
| Age (years)         | 58.9(13.74)    | 40  | 83  | 67.0 (11.6)    | 45  | 83  |
| Disease duration (years) | 6.2(3.7)     | 0.08| 26  | 5.8(4.2)       | 0.06| 14  |
| H&Y                 | 2.39(1.09)     | 1   | 6   | 2.34(1.28)     | 1   | 4   |
| Daily L-dopa dosage (mg) | 392.3(225.3) | 200 | 800 | 383.3(189.9)  | 200 | 800 |
| BMI                 | 22.80(2.12)    | 19.22| 25.39| 21.68(3.37)   | 18.32| 25.39|
| MMSE                | 25.32(2.18)    | 21  | 30  | 22.08(2.93)   | 18  | 30  |
| UPDRS(III)          | 17.89(5.65)    | 6   | 29  | 19.23(10.60)  | 8   | 33  |
| NMSS(total)         | 131.14(9.24)   | 47  | 219 | 135.57(48.76) | 41  | 235 |
| Cardiovascular      | 2.21(3.87)     | 0   | 9   | 2.64(3.31)    | 0   | 8   |
| Sleep/Fatigue       | 28.14(3.92)    | 0   | 46  | 26.57(10.11)  | 0   | 46  |
| Mood                | 27.14(13.31)   | 0   | 58  | 26.43(12.38)  | 0   | 55  |
| Perceptual problem  | 7.36(3.42)     | 0   | 22  | 9.71(7.67)    | 0   | 26  |
| Attention/memory    | 13.29(6.60)    | 0   | 22  | 13.07(4.42)   | 0   | 21  |
| Gastrointestinal    | 11.57(9.15)    | 0   | 32  | 12.57(8.78)   | 0   | 31  |
| Urinary             | 13.21(9.93)    | 0   | 32  | 12.36(8.10)   | 0   | 36  |
| Sexual function     | 13.64(5.0)     | 0   | 24  | 15.86(6.8)    | 0   | 24  |
| Miscellaneous       | 15.64(10.72)   | 0   | 36  | 16.36(9.79)   | 0   | 38  |

Abbreviations: SD, Standard deviation; BMI, Body Mass Index; MMSE, mini-mental state examination; UPDRS III, the unified Parkinson’s disease rating scale part III; H&Y, the modified Hoehn and Yahr staging scale; and NMSS, non-motor symptoms scale for Parkinson’s disease (range of possible scores from 0 to 360).

doi:10.1371/journal.pone.0019333.t001
Statistical analysis

All data for the continuous variables (age, disease duration, daily levodopa dosage, UPDRS III, MMSE, NMSS, Hcy, and CRP) are shown as the means ± standard deviation, and the categorical variable (gender) is shown as a percentage. The total scores of UPDRS III, MMSE, NMSS, Hcy, and CRP were calculated by summing single items. The strength of the association for correlation coefficients was interpreted as follows: ≤0.19, negligible; 0.20 to 0.39, weak; 0.40 to 0.59, moderate; 0.60 to 0.79, strong; and ≥0.80, very strong [25]. Student’s t-test was used to compare the differences of age, Hcy, CRP, BMI, MMSE, UPDRS III, and NMSS between PD and VP patients. A Spearman’s rank correlation coefficient was used to evaluate the association among UPDRS III and Hcy/CRP, UPDRS III and MMSE/NMSS, nine different NMSS domains and Hcy/CRP, Hcy/CRP and H&Y, H&Y and MMSE/NMSS, Hcy/CRP and L-dopa dosage, and Hcy/CRP and disease duration. The variables tested included age, disease duration, H&Y, MMSE, NMSS, UPDRS III, Hcy and CRP. SPSS 13.0 software (Chicago, IL, USA) was used for the statistical analyses. P values of less than 0.05 were regarded as statistically significant.

Results

Patient characteristics

In total, 88 PD subjects, including 43 PD patients (25 males (58.1%) and 18 females (41.9%)) and 45 VP patients (25 males (51.1%) and 22 females (49.9%)), were enrolled in this cross-sectional study. The mean ages of the PD and VP patients were 58 ± 13.74 years (range, 43 to 83) and 67 ± 11.6 years (range, 45 to 83), respectively. The mean durations of PD and VP symptoms were 6.2 ± 3.7 years (range, 0.08 to 26) and 5.8 ± 4.2 years (range, 0.06 to 14), respectively. The H&Y stages ranged from 1 to 4 for patients with PD and VP. With respect to the levodopa (L-dopa) therapy, the average dosages were 392.3 mg and 303.3 mg daily for PD and VP, respectively. Details of the demographics of all 88 patients are listed in Table 1.

The mean age for patients with VP was higher than that in the PD patients (67.03 ± 58.88, P = 0.006), and the MMSE for patients with VP was lower than that in PD patients (22.08 vs. 25.32, P = 0.007, Table 2). No significant difference in the Hcy, CRP, BMI, UPDRS III, or nine dimensions of NMSS was found between the PD and VP patients.

When the PD and VP subjects were divided into two groups (age ≤ 60, age > 60), the levels of CRP in the PD patients above 60 years old were significantly higher than those in the PD patients younger than 60 years old (3.04 vs. 1.47, P = 0.005, Table 3), and the levels of Hcy in VP patients above 67 years old were significantly higher than those in VP patients younger than 67 years old (16.79 vs. 12.78, P = 0.009, Table 3).

Correlations between UPDRS III and Hcy/CRP, UPDRS III and MMSE, NMSS domains and Hcy/CRP, Hcy/CRP and H&Y, Hcy/CRP and L-dopa dosage, Hcy/CRP and disease duration, and Hcy/CRP and MMSE

There was a significant correlation between UPDRS III and CRP (rS = 0.56, P = 0.011, Table 4) as well as between UPDRS III and NMSS (rS = 0.55, P = 0.042, Table 4) in patients with PD.

Table 2. Comparison of age, BMI, Hcy, CRP, UPDRS (III), MMSE, and NMSS between PD and VP

| Variable                  | PD          | VP          | T value | P value |
|---------------------------|-------------|-------------|---------|---------|
| Age                       | 58.88 ± 13.7| 67.03 ± 11.58| 2.809   | 0.006*  |
| Hcy                       | 14.08 ± 0.77| 15.12 ± 0.90| 0.087   | 0.39    |
| BMI                       | 2.06 ± 0.28 | 2.59 ± 0.39 | 1.136   | 0.26    |
| CRP                       | 22.80 ± 2.12| 21.68 ± 2.37| 1.247   | 0.224   |
| MMSE                      | 25.32 ± 2.18| 22.08 ± 2.93| 2.955   | 0.007*  |
| UPDRS(III)                | 17.89 ± 5.65| 19.23 ± 10.60| 0.389   | 0.701   |
| NMSS (total)              | 131.14 ± 9.24| 135.57 ± 48.76| 0.671   | 0.508   |
| Cardiovascular            | 2.21 ± 2.39 | 2.64 ± 2.31 | −0.483  | 0.633   |
| Sleep/Fatigue             | 28.14 ± 9.69| 26.57 ± 10.11| 0.420   | 0.678   |
| Mood                      | 27.14 ± 13.31| 26.43 ± 12.38| 0.144   | 0.886   |
| Perceptual problem        | 7.36 ± 7.06 | 9.71 ± 7.67 | −0.846  | 0.405   |
| Attention/ memory         | 13.29 ± 6.60| 13.07 ± 7.56 | 0.081   | 0.936   |
| Gastrointestinal          | 11.57 ± 9.75| 12.57 ± 8.78 | −0.285  | 0.778   |
| Urinary                   | 13.21 ± 7.91| 12.36 ± 8.10 | 0.283   | 0.779   |
| Sexual function           | 13.64 ± 6.29| 15.88 ± 6.8 | −0.894  | 0.380   |
| Miscellaneous             | 15.64 ± 10.72| 16.36 ± 9.79 | −0.192  | 0.849   |

* P < 0.01.

Abbreviations: SD, Standard deviation; BMI, Body Mass Index; MMSE, mini-mental state examination; UPDRS III, the unified Parkinson’s disease rating scale part III; and NMSS, non-motor symptoms scale for Parkinson’s disease (range of possible scores from 0 to 360).
CRP and disease duration in patients with PD.

Correlations were found between Hcy/CRP and MMSE and Hcy/with H&Y (P = 0.009). Similarly, the CRP and NMSS also strongly correlated with NMSS (rS = 0.602, P = 0.01, Table 5). Specifically, when evaluating the correlation between CRP and the different NMSS dimensions in PD and VP, significant correlations, from low to high, were observed in miscellaneous (P = 0.013 for VP), urinary (P = 0.004 for VP), sleep/fatigue (P = 0.001 for VP), and mood (P = 0.001 for PD). Similarly, when evaluating the correlation between CRP and the different NMSS dimensions in PD and VP, significant correlations, from low to high, were observed in mood (P = 0.01 for PD), urinary (P = 0.004 for PD), sleep/fatigue (P = 0.001 for PD), and gastrointestinal (P = 0.004 for PD), urinary (P < 0.001 for PD), and mood (P = 0.001 for PD). For the remaining four dimensions, no significant correlations were found (Table 5). In addition, Hcy/CRP were significantly associated with L-dopa dosage for both PD and VP patients (P < 0.001, Table 6), and Hcy/CRP were correlated with H&Y (P < 0.01, Table 6) in PD patients. No significant correlations were found between Hcy/CRP and MMSE and Hcy/CRP and disease duration in patients with PD.

Discussion

PD is the second most common neurodegenerative disorder following AD and is characterized by a disturbance of the central dopaminergic system; the concept of VP was first mentioned by Critchley in 1929 [29]. Over the past few years, correlations between VP and PD patients have received significant attention in the diagnosis, therapy, and evaluation of these two diseases [17, 26, 27, 28]. The primary goals of this study were to compare Chinese patients with PD and VP by systematically collecting information about demographics, such as age and disease duration, motor and non-motor dysfunctions, and the serum levels of CRP and Hcy. To the best of our knowledge, this report is the first to evaluate the association between motor/non-motor effects and CRP/Hcy in Chinese patients with PD and VP using unified and integrated scales (NMSS, H&Y, and MMSE).

In this study, the VP group presented many characteristics, such as resting tremor, postural instability, and rigidity, that are similar to those described in the original VP report by Critchley [29]. We found that NMS (including cardiovascular, sleep, and mood disorders) were very common in Chinese patients with PD and VP, with a prevalence of NMS in the group being 100%, and the NMSS for PD (mean = 131.14, Table 1) was consistent with a previous report [15]. However, we did not find a significant difference in NMS between PD and VP, which suggests that NMS equally influenced PD and VP in Chinese subjects. Interestingly, as shown in Tables 1 and 2, our patients with VP were significantly older than those patients with PD, and a shorter duration of symptoms in the VP group was also observed. This finding has also been documented in some other VP studies [26, 27], and it implies that Chinese VP subjects developed symptoms later in life but experienced deterioration faster than the PD patients. Additionally, a later age at onset of VP would favor a vascular cause. Interestingly, a significant reduction of the MMSE was observed in VP patients when compared to the PD group (mean = 25.32 for PD, mean = 22.08 for VP, P = 0.007, Table 2). This result demonstrated that compared to PD subjects, Chinese VP patients had already undergone a greater decline in cognitive function by the time they visited a neurologist. This result is in agreement with Zijlmans’ point [17] and implies that our VP patients may have more subcortical lesions than patients with PD and that this subcortical vascular cause may have led to the declined cognition.

Recent studies have shown that inflammatory responses are observed in the nigrostriatal regions of dopaminergic degeneration, and some protective strategies against inflammatory development occur when anti-inflammatory medications are taken. Among those inflammatory mediators, Hcy and CRP have received substantial attention for the past 15 years as having an important role in and potentially as risk factors for PD. An

Table 3. Comparison of Hcy and CRP among patients with PD and VP.

| Variable | PD | VP |
|----------|----|----|
|          | Age≤60 | Age>60 | Age≤67 | Age>67 | P |
| Hcy      | 14.50±5.82 | 13.65±3.18 | 0.604 | 12.78±3.86 | 16.79±5.55 | 0.509* |
| CRP      | 1.47±0.96 | 3.04±2.21 | 0.005* | 3.31±0.91 | 3.27±0.82 | 0.97 |

* P<0.01

Table 4. Spearman’s rank correlation coefficient (r) and P values between UPDRS III and clinical variables, and between H&Y and clinical variables.

| Variable | UPDRS(III) (PD) | H&Y (PD) | UPDRS(III) (VP) | H&Y (VP) |
|----------|----------------|----------|----------------|----------|
| Hcy      | 0.463          | 0.759    | 0.216          | 0.637    | 0.014* |
| CRP      | 0.656          | 0.852    | 0.013          | 0.453    | 0.104  |
| BMI      | −0.053         | 0.191    | 0.132          | 0.431    | 0.124  |
| MMSE     | −0.308         | 0.262    | −0.203         | −0.522   | 0.056  |
| NMSS (total) | 0.550  | 0.602    | 0.318          | 0.735    | 0.040* |

* P<0.05, ** P<0.001

Abbreviations: rs, Spearman’s rank correlation coefficient; H&Y, the modified Hoehn and Yahr staging scale; UPDRS III, the unified Parkinson’s disease rating scale part III; MMSE, mini-mental state examination; NMSS, non-motor symptoms scale for Parkinson’s disease.

doi:10.1371/journal.pone.0019333.t003
elevated plasma Hcy level represents a risk factor for declined cognition and dementia in the general population [30], and it has been well documented to be associated with mild cognitive impairment (MCI), Alzheimer’s disease (AD), PD, and vascular dementia [7,11,31]. Similarly, increased plasma CRP is correlated to myocardial infarction, PD, and ischemic stroke [6,32]. However, limited studies have investigated the association of the combination of Hcy and CRP in PD and VP subjects. To clarify, to determine if Hcy and CRP contribute to the motor dysfunction and cognitive decline in VP and PD patients, we examined the plasma Hcy/CRP and compared their levels in PD and VP patients. Our data did not show a significant difference in Hcy and CRP between the PD and VP groups (Table 2). This result demonstrates that the inflammatory mediators Hcy and CRP might contribute equally to the progression of these two diseases. Interestingly, when we separated the subjects into two groups according to age (<60 and >60), we noticed that the CRP levels in PD subjects above 60 years old were much higher than those patients under 60, whereas the Hcy levels in VP subjects above 60 were less than those under 60 (Table 3). Two reasons probably led to the discrepancy in the CRP and Hcy levels in patients with PD. First, as a neurodegenerative disease, PD exacerbates with age, and the inflammatory process aggravates the progression in PD patients above 60 when compared to patients under 60. This exacerbated inflammatory response in PD patients above 60 can be reflected in the obviously elevated levels of CRP, a biomarker of systemic inflammation. Second, Hcy, though recognized as an indicator of neurotoxic mediator, is profoundly affected by several factors, such as some B-vitamin (folate, and B12, and B6) deficiencies, genetic polymorphisms of MTHFR and CßS, and L-dopa intake [11,33]. These influences may lead to the unchanged level of Hcy between PD patients above and under 60 in this study. We did not observe a significantly changed level of CRP, but we did observe a significant upregulation of Hcy in VP patients above 67 when compared with those under 67. The precise reasons remain unclear, but it may reflect a different pathogenesis for PD and VP, the latter of which mainly results from subcortical vascular causes; additionally, Hcy is obviously

### Table 5. Spearman’s rank correlation coefficient (r) and P values between NMSS domains and Hcy, and between NMSS domains and CRP.

| Variable     | Hcy (PD) | CRP (PD) | Hcy (VP) | CRP (VP) |
|--------------|----------|----------|----------|----------|
| r            | r        | r        | r        | r        |
| p            | p        | p        | p        | p        |
| NMSS (total) | 0.795    | 0.001**  | 0.781    | 0.001**  |
| Cardiovascular | 0.503    | 0.067    | 0.474    | 0.087    |
| Sleep/Fatigue | 0.478    | 0.084    | 0.477    | 0.084    |
| Mood         | 0.767    | 0.001**  | 0.801    | 0.001**  |
| Perceptual problem | 0.528    | 0.052    | 0.649    | 0.012*   |
| Attention/memory | 0.232    | 0.424    | 0.224    | 0.440    |
| Gastrointestinal | 0.485    | 0.078    | 0.722    | 0.004**  |
| Urinary      | 0.668    | 0.009**  | 0.660    | 0.010*   |
| Sexual function | 0.299    | 0.299    | 0.162    | 0.580    |
| Miscellaneous | 0.461    | 0.067    | 0.133    | 0.650    |

* P < 0.05, ** P < 0.01, *** P < 0.001.

Abbreviations: r, Spearman’s rank correlation coefficient; NMSS, non-motor symptoms scale.

### Table 6. Spearman’s rank correlation coefficient (r) and P values between Hcy and clinical variables, and between CRP and clinical variables.

| Variable       | Hcy (PD) | CRP (PD) | Hcy (VP) | CRP (VP) |
|----------------|----------|----------|----------|----------|
| r              | r        | r        | r        | r        |
| p              | p        | p        | p        | p        |
| Hcy            | 1        | 0.912    | 0.000*** | 1        |
| CRP            | 0.912    | 0.000*** | 1        | 0.686    |
| Daily L-dopa dosage | 0.814    | 0.000*** | 0.693    | 0.006**  |
| H&Y            | 0.759    | 0.002**  | 0.852    | 0.000*** |
| Disease duration | 0.480    | 0.098    | 0.447    | 0.109    |
| MMSE           | 0.431    | 0.124    | −0.387   | 0.171    |

* P < 0.05, ** P < 0.01, *** P < 0.001.

Abbreviations: r, Spearman’s rank correlation coefficient; H&Y, the modified Hoehn and Yahr staging scale; MMSE, mini-mental state examination.

doi:10.1371/journal.pone.0019333.t005
doi:10.1371/journal.pone.0019333.t006
increased in cerebral-vascular diseases [28,33,34,35]. Our findings suggest that the chronic inflammatory response may be worse in older PD patients and that an anti-inflammatory strategy would be useful in the management of PD.

Spearman’s rank correlation coefficients were determined to explore the association of UPDRS III with the Hcy, CRP, H&Y, MMSE and NMSS in PD and VP. Similar to our previous report [15], highly significant correlations were observed between motor dysfunctions and NMS burden in patients with PD ($r_s = 0.550$, $P = 0.042$, Table 4). This result suggests that both disease severity and motor dysfunctions may influence NMS in PD and that NMS may have multiple effects on the motor complications in PD. Interestingly, no correlations were found between the UPDRS III and Hcy in PD ($r_s = 0.463$, $P = 0.096$, Table 4) and VP ($r_s = 0.216$, $P = 0.459$, Table 4) or between the UPDRS III and CRP in VP ($r_s = 0.013$, $P = 0.964$, Table 4). However, similar to the result in Table 3, the inflammatory mediator CRP was closely correlated to UPDRS III in the PD group ($r_s = 0.656$, $P = 0.011$, Table 4), further demonstrating that the inflammatory response in PD patients may contribute to motor dysfunction [36].

To further correlate the association of the individual domains of NMS with Hcy, CRP, and H&Y, we identified that some dimensions of NMS in PD and VP significantly correlated with NMS with Hcy, CRP, and H&Y, we identified that some patients may contribute to motor dysfunction [36].

In conclusion, our findings support the hypothesis that as exquisitely sensitive systemic mediators of inflammation, Hcy and CRP play important roles in the pathogenesis of PD. To our best knowledge, this report is the first to combine the plasma levels of Hcy and CRP to assess the progression of PD and VP. The combination of Hcy and CRP, especially CRP, may predict the outcomes of non-motor dysfunctions in PD and VP. A causal link in either direction is feasible; a systemic Hcy and CRP change may predispose a person to PD or VP or otherwise impair dopaminergic neuronal function. Alternatively, worse parkinsonism may predispose a person to the alteration of Hcy and CRP due to some medication factors, such as L-dopa treatment. Our findings, if confirmed, indicate that disease burden in patients with PD and VP, such as poor motor performance, disease severity, and urinary dysfunction, is associated with plasma Hcy and CRP levels. Whether or not anti-inflammatory medication could be used in the management of PD and VP will produce interesting work in the future.

Author Contributions
Conceived and designed the experiments: LMZ, JQY, QW. Performed the experiments: LMZ, JQY QX LL. Analyzed the data: JQY LL CSZ LJY. Contributed reagents/materials/analysis tools: XHC YJ LFB. Wrote the paper: LMZ, JQY QW.

References
1. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A (2008) Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 167(7): 90–95.
2. Saiki M, Baker A, Williams-Gray CH, Folytine T, Goodman RS, et al. (2010) Association of the human leukocyte antigen region with susceptibility to Parkinson’s disease. J Neurol Neurosurg Psychiatry 81(8): 890–891.
3. Setz RC, Lee CY, Lin EC, Tan JJ, Quek AM, et al. (2010) Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. Free Radic Biol Med 48(4): 560–566.
4. Przedborski S (2010) Inflammation and Parkinson’s disease pathogenesis. Mov Disord 25(Suppl 1): S55–57.
5. Song IU, Chung SW, Kim JS, Lee KS (2010) Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson’s disease. Neurology 62(3): 199–204.
6. Song IU, Kim JS, Chung SW, Lee KS (2009) Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson’s disease? A comparison of Parkinson’s disease patients, disease controls and healthy individuals. Eur Neurol 62(2): 99–104.
7. Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Lamer I, Pagonabarraga J, et al. (2009) Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord 24(10): 1437–1444.
8. Zoccolcella S, dell’Aquila C, Abbruzzese G, Antonini A, Bonaccelli U, et al. (2009) Hyperhomocysteinemia in levodopa-treated patients with Parkinson’s disease dementia. Mov Disord 24(7): 1028–1033.
9. Müller T, Kuhn W (2009) Homocysteine levels after acute levodopa intake in patients with Parkinson’s disease. Mov Disord 24(9): 1339–1343.
10. Müller T, Kuhn W (2009) Cysteine elevation in levodopa-treated patients with Parkinson’s disease. Mov Disord 24(9): 929–932.
11. Zoccolcella S, dell’Aquila C, Specchio LM, Logroscino G, Lambert P (2010) Elevated homocysteine levels in Parkinson’s disease: is there anything besides levodopa treatment? Curr Med Chem 17(3): 213–221.
12. Camicioli RM, Bouchard TP, Somerville MJ (2009) Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson’s disease patients. Mov Disord 24(2): 176–182.
13. Louis ED, Schupf N, Tang MX, Marder K, Luchinger JA (2007) Mild parkinsonian signs and plasma homocysteine concentration in community-dwelling elderly individuals. Arch Neurol 64(11): 1646–1651.
14. Pfeiffer RF (2009) Parkinson disease. Nonmotor symptoms in Parkinson disease: the PRIAMO study. Nat Rev Neurol 5: 531–532.
15. Li H, Zhang M, Chen L, Zhang J, Pei Z, et al. (2010) Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson’s disease. Mov Disord. In press.
16. Hughes AJ, Daniel SE, Kiflold L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 53: 101–104.
17. Zijlmans JC, Daniel SE, Hughes AJ, Révész T, Lees AJ (2004) Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 19(6): 630–640.
18. Klepac N, Hajnsek S, Trkulja V (2010) Impact of pre-morbid depression on health-related quality of life in non-demented Parkinson’s disease patients. Parkinsonism Relat Disord 16: 21–27.
19. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198.
20. Benamer HT, Grosset DG (2009) Vascular parkinsonism: a clinical review. Eur Neurol 61(1): 11–15. Review.
21. Fahn S, Elton R, Members of the UPDRS development committee (1987) The unified Parkinson disease rating scale. Macmillan Health Care Information.
22. Hoyer MM, Yah MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442.
23. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, et al. (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study. Mov Disord 22: 1901–1911.
24. Ichikawa Y, Ohno J, Suzuki M, Azzo T, Sugino M, et al. (2002) Higher C-reactive protein concentration and white blood cell count in subjects with more coronary risk factors and/or lower physical fitness among apparently healthy Japanese Circ J 66(7): 677–684.
25. Swinscow TD (1997) Correlation and regression Statistics at square one, 9th ed. University of Southampton: BMJ Publishing Group.
26. Kalra S, Grosset DG, Benamer HT (2010) Differentiating vascular parkinsonism from idiopathic Parkinson’s disease: a systematic review. Mov Disord 25(2): 149–156.
27. Winikates J, Jankovic J (1999) Clinical correlates of vascular parkinsonism. Arch Neurol 56(1): 96–102.
28. Zijlmans J, Evans A, Fontes F, Katzenschlager R, Gacicovcic S, et al. (2007) [123I] FP-CIT spect study in vascular parkinsonism and Parkinson’s disease. Mov Disord 22(9): 1278–1283.
29. Crichtley M (1929) Arteriosclerotic parkinsonism. Brain 52: 23–83.
30. Prins ND, Den Hoest J, Hofman A, Koudstaal PJ, Jolles J, et al. (2002) Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology 59: 1373–1380.
31. Seshadri S, Bierer A, Sellub J, Jacques PF, Rosenberg HI, et al. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 346: 476–483.
32. Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG (2010) Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 68(3): 672–680.
33. Rogers JD, Sanchez-Saffon A, Frodl AB, Diaz-Arrastia R (2005) Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 62(1): 59–64.
34. Zijlmans JC, Thijsen HO, Vogels OF, Kremer HP, Pooy PJ, et al. (1995) MRI in patients with suspected vascular parkinsonism. Neurology 45: 2183–2188.
35. Zijlmans JC, Katzenschlager R, Daniel SE, Lees AJ (2004) The L-dopa response in vascular parkinsonism. J Neurol Neurosurg Psychiatry 75(4): 543–547.
36. Duke M, Hammadov M, Lokaj K, Goldmuntz D, Rokottov I, et al. (2009) Serum inflammatory biomarkers in Parkinson’s disease. Parkinsonism Relat Disord 15(4): 318–320.
37. O’Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB Jr., et al. (2004) Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61(8): 863–868.
38. Lamberti P, Zoccolcella S, Iliceto G, Armenise E, Fraddosia A, et al. (2005) Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson’s disease patients. Mov Disord 20(1): 69–72.
39. Lamberti P, Zoccolcella S, Armenise E, Lamberti SV, Fraddosia A, et al. (2005) Hyperhomocysteinemia in L-dopa treated Parkinson’s disease patients: effect of cobalamin and folate administration. Eur J Neurol 12(5): 363–368.
40. Barone P, Burn DJ, van Laar T, Hsu C, Poeve W, et al. (2008) Rivastigmine versus placebo in hyperhomocysteinemic Parkinson’s disease dementia patients. Mov Disord 23: 1532–1540.